Director

Allison Schneider, MHA

Allison joined ADVI as an Associate in June 2022. She mainly works in the pharmaceutical and diagnostics space, assisting clients with a range of issues including health reform legislation and subsequent federal and state implementation.

Allison comes to ADVI Health with experience in health policy at the nonprofit, state, and federal levels. Most recently, she was a Public Health Advisor at the Centers for Disease Control and Prevention’s National Center for Immunization and Respiratory Diseases. Her work in this role supported the Center director. She managed projects related to immunization policy and helped facilitate the CDC’s COVID-19 response, coordinating briefings with state and federal officials. 

Before this position Allison worked as a CDC fellow researching state-level health regulations, resulting in multiple journal articles and national presentations. She also led several working groups and authored numerous articles, policy statements, and guidance materials. Throughout her graduate and undergraduate programs she worked with several senators and nonprofits, becoming versed in issues related to healthcare reform, coverage, reimbursement, and public health.

CEO insights

Real analysis from people who’ve been there

ADVI Angle Vertical

Rare Disease State Policy

Prescription Drug Affordability Boards: Access Concerns and Implications for Rare Diseases and Conditions

In recent years, states have increasingly enacted Prescription Drug Affordability Boards (PDABs). While their stated purpose is to increase affordability, …

Allison Schneider, MHA
February 28, 2025

Inflation Reduction Act Pharmaceuticals and Biotech State Policy

ADVI Instant: CMS Releases 2026 Notice of Benefit and Payment Parameters Proposed Rule

On October 4, 2024, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule titled “HHS Notice of …

Brenna Raines, MHA
October 21, 2024

Pharmaceuticals and Biotech

ADVI Analysis: MedPAC October 2024 Meeting

MedPAC held a meeting on October 10-11, 2024 (link). The following relevant topics were discussed: ADVI Angle Key takeaways from …

Allison Schneider, MHA
October 21, 2024

Pharmaceuticals and Biotech

ADVI Analysis: MedPAC September 2024 Meeting

MedPAC held a meeting September 5, 2024 (link). The following relevant topics were discussed:  ADVI Angle Key takeaways from the …

Allison Schneider, MHA
September 17, 2024

Pharmaceuticals and Biotech State Policy

ADVI Instant: Colorado PDAB Votes to Establish an Upper Payment Limit for Enbrel

On February 23, 2024, the Colorado Prescription Drug Affordability Board (PDAB) voted unanimously to move forward with establishing an upper …

Allison Schneider, MHA
February 29, 2024

Pharmaceuticals and Biotech State Policy

ADVI Analysis: The Colorado PDAB Meeting: February 16, 2024

Executive Summary On February 16, 2024, the Colorado Prescription Drug Affordability Board (PDAB) held a meeting to vote on whether …

Allison Schneider, MHA
February 22, 2024

Pharmaceuticals and Biotech

ADVI Instant: FDA Authorizes Florida’s Drug Importation Program

On January 5, 2024, the Food and Drug Administration (FDA) announced that it authorized Florida’s drug importation program under section 804 of …

Allison Schneider, MHA
January 11, 2024

Pharmaceuticals and Biotech

ADVI Analysis: MACPAC December 2023 Meeting

MACPAC held a meeting December, 14-15, 2023 (link). The following relevant topics were discussed: ADVI Angle Key takeaways from the …

Allison Schneider, MHA
December 22, 2023

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.